Skip to Content

Other Cancer Trials

Alliance A151804: Establishment of a National Biorespository to Advance Studies of Immune-Related Adverse Events
Aims: The purpose of this study is to gather information about why do some patients experience serious side effects from immunotherapies,how can we identify these patients, and how to prevent, reduce, and treat these side effects more effectively.
Diagnosis: Any cancer
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH20-292
Sponsor: Alliance
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

ACCRU SC1601: A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondard Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Aims: The purpose of this study is to gather information regarding the extension of time of treatment on oral anticoagulants.
Diagnosis: Any cancer except leukemia
Principal Investigator: Afonso Tafur, MD
IRB Approval Number: EH17-300
Sponsor: Academic and Community Cancer Research United
Contact: For further information, please contact Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

A221602: Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) A Phase III Randomized, Double-Bline, Placebo-Controlled Trial
Aims: The purpose of this study is to see if olanzapine without fosaprepitant is as effective as olanzapine with fosaprepitant.
Diagnosis: Any cancer receiving HEC
Principal Investigator: Lauren Wiebe, MD
IRB Approval Number: EH19-182
Sponsor: Alliance
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

Prospective Analysis of the Utility of Routine Incorporation of Genomic Panels into the Care of Patients with Metastatic Cancer
Aims: The purpose of this research is to learn how best to perform and use gene testing in cancer patients
Diagnosis: any patient with solid tumor
Principal Investigator: Bruce Brockstein and Karen Kaul
IRB Approval Number: EH20-392
Sponsor: NorthShore
Contact: For further information, please contact Annette Sereika at 847-570-2735
Open to Enrollment: Yes

EAY131: Molecular Analysis for Therapy Choice (MATCH)
Aims: This study will look at assigning treatment for patients whose cancer has become worse after standard treatment. Patients will have a genomic analysis of their tumor which will direct appropriate targeted therapy.
Diagnosis: any solid tumor
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH15-387
Sponsor: ECOG-ACRIN/NCI 
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes (limited)